Why Did ANRO Stock Jump in Premarket: FDA Fast Track Schizophrenia Drug
-
最新报道：Alto Neuroscience's stock (NYSE: ANRO) surged 6.05% to $4.73 in premarket trading after the FDA granted Fast Track designation to ALTO-101, its investigational treatment for cognitive impairment in schizophrenia. The designation expedites development for a condition with no approved therapies, following positive Phase 1 results showing improved cognitive function. ANRO's market cap stands at $119 million, with analysts maintaining strong buy ratings and price targets up to $15.
下一篇
Analysis: Ethereum shows bullish trend in October, but long-term sentiment remains cautious
- According to the Bijie.com news, on October 3, Thahbib Rahman, a research analyst at Block...
24小时热点
热点专题
418154